C-MER Eye Care Unit Invests $1 Million in Oral Anti-Cancer Drug Company

MT Newswires Live01-03

C-MER Eye Care (HKG:3309) subsidiary C-MER Medical Group will invest $1 million into clinical-stage biotech company Health Hope Pharma.

The investment is part of the HHP Series A fundraising round, according to a Dec. 31 filing with the Hong Kong Exchange.

HHP produces oral anti-cancer drugs, the filing said.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment